Latest news

• EMA says Lilly’s Lartruvo should not be prescribed

  Lilly claimed EMA approval for Lartruvo (olaratumab) for the first-line treatment of advanced soft tissue sarcoma (STS) in 2016, when it became the first new drug for patients with the

• Lilly bags EU approval for cancer treatment Lartruvo

  Dr Sue Mahony, president of Lilly Oncology, said: “With this decision, olaratumab is now authorised for use in the EU, offering a new treatment option for soft tissue sarcoma patients in

• Lilly snags first approval for sarcoma drug Lartruvo

  The US FDA granted accelerated approval to Lartruvo (olaratumab) used in combination with doxorubicin chemotherapy in STS patients who cannot be cured using surgery or radiotherapy, and who have a form

• Lilly closes on first approval for sarcoma drug Lartruvo

  The EMA panel gave a green light to a conditional approval of Lartruvo (olaratumab), used in combination with doxorubicin chemotherapy, for advanced STS patients who cannot be treated with surgery or ... Olaratumab is also under regulatory review in the

• Lilly planning 20 new launches by 2023

  Top projects include PDGF inhibitor olaratumab, which was granted priority review by the FDA earlier this month for soft tissue sarcoma, and CDK4/6 inhibitor abemaciclib for advanced breast cancer and ... Olaratumab will see its first marketing